Okay, let's tackle this question. The user is asking about the most sensitive screening test for prostate cancer, especially in a 50-year-old male with a family history. First, I need to recall the standard screening methods for prostate cancer.

The options probably include digital rectal exam (DRE) and prostate-specific antigen (PSA) test. I remember that PSA is a blood test, while DRE is a physical exam. Sensitivity refers to how often the test correctly identifies those with the disease. Since PSA levels can be elevated in benign conditions like BPH or prostatitis, it might have higher sensitivity but lower specificity. DRE might miss smaller tumors, so it's less sensitive.

Wait, the question is about sensitivity, not specificity. So the most sensitive test would be the one that catches more cases. PSA is known to detect early cancers that DRE might miss. So the correct answer is likely PSA. The other options might be DRE, transrectal ultrasound, or MRI. DRE is less sensitive. Transrectal ultrasound is not typically a screening test but used for biopsy guidance. MRI is more specific but not routine for initial screening.

I need to make sure there's no newer test like PCA3 or 4Kscore, but those are not standard. The standard screening is PSA and DRE. Since the question is about sensitivity, PSA is more sensitive. The clinical pearl here is that while PSA is sensitive, it's not specific, leading to overdiagnosis. But the question specifically asks for sensitivity, so PSA is correct.

**Core Concept**
Prostate cancer screening involves balancing sensitivity and specificity. **Prostate-specific antigen (PSA)** testing is the most sensitive screening method, detecting early neoplastic changes by measuring serum levels of a glycoprotein produced by prostate epithelial cells. Digital rectal examination (DRE) is less sensitive but more specific for palpable abnormalities.

**Why the Correct Answer is Right**
**PSA testing** (Correct Answer: B) elevates in benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. Its high sensitivity stems from detecting microscopic cancer foci undetectable by DRE. However, false positives are common due to non-malignant conditions. The PSA assay quantifies antigen levels, with thresholds like ≥4 ng/mL prompting further evaluation (e.g., biopsy). While transrectal ultrasound (TRUS) and MRI are imaging modalities, they lack standalone screening sensitivity.

**Why Each Wrong Option is Incorrect**
**Option A: Digital Rectal Examination (DRE)** – Less sensitive than PSA, as it only identifies palpable tumors, missing small or non-palpable lesions.
**Option C: Transrectal Ultrasound (TRUS)** – Not a screening test; used for biopsy guidance after abnormal PSA/DRE.
**Option D: MRI** – High specificity but not routinely used for initial screening due to cost and limited sensitivity for early-stage disease.

**Clinical Pearl / High-Yield Fact**
Remember: **PSA = sensitivity, DRE = specificity**. The USPSTF recommends shared decision-making for PSA screening in men aged 55–69 due to its trade-off between early detection and overdiagnosis. Always correlate PSA with DRE and imaging for confirmation.

**Correct Answer: B. Prostate-specific antigen (PS

✓ Correct Answer: C. DRE + PSA